Development and clinical significance of a diagnostic assay based on the polymerase chain reaction for detection of human cytomegalovirus DNA in blood samples from immunocompromised patients.
about
New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipientsEvaluation of new quantitative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patientsHuman cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipientsQuantitation of cytomegalovirus (CMV) DNA in leukocytes of human immunodeficiency virus-infected subjects with and without CMV disease by using PCR and the SHARP Signal Detection SystemApplication of PCR to multiple specimen types for diagnosis of cytomegalovirus infection: comparison with cell culture and shell vial assay.Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients.Human cytomegalovirus (HCMV) late-mRNA detection in peripheral blood of AIDS patients: diagnostic value for HCMV disease compared with those of viral culture and HCMV DNA detectionQualitative and semiquantitative polymerase chain reaction testing for cytomegalovirus DNA in serum allows prediction of CMV related disease in liver transplant recipients.Clinical significance of expression of human cytomegalovirus pp67 late transcript in heart, lung, and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification.Quantitation of cytomegalovirus: methodologic aspects and clinical applications.Utility of major leukocyte subpopulations for monitoring secondary cytomegalovirus infections in renal-allograft recipients by PCR.Long-term predictive value of a single cytomegalovirus (CMV) DNA PCR assay for CMV disease in human immunodeficiency virus-infected patients.A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolateSingle amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovEvaluation of the Digene Hybrid Capture System for detection and quantitation of human cytomegalovirus viremia in human immunodeficiency virus-infected patients.Comparison of nested PCR for detection of DNA in plasma with pp65 leukocytic antigenemia procedure for diagnosis of human cytomegalovirus infection.
P2860
Q33812425-24E2D1DE-F98D-416F-B0C5-7BFA0D4F38A6Q33962859-232112AC-669A-4CD5-BA09-594438234D55Q33966910-BB1AF8B6-F708-4E7A-945E-0973F991A217Q36543316-760B2BDA-A4D6-4AD5-8E94-A19BB12844F5Q37069375-96995B6A-8DA6-4262-95F4-7B29EEBEE027Q37095025-8FF6F42E-D122-48B6-BC92-BC5E0F35DCC0Q37130831-6A71F361-4270-4B01-B762-9600E87D75EEQ37229975-3D1FBF99-54BC-48F5-B823-47C06D7F407BQ39467685-9994A91C-7486-49E6-8CD3-00BB152A7BBEQ39468915-8B5F3606-2C13-4FE5-88B1-FE7CD914EEBEQ39552968-DFE758A6-CAE0-4F58-9A2C-265C18C1F03BQ39643253-DC7EAD13-1140-4745-975E-894C3122532AQ39868666-89C92E66-CF70-4889-82BA-9686F5D5F5FFQ39873608-C0E80FF0-4F84-462D-9EB1-C67D041FFFD6Q40012406-79CD8BB3-5706-4E9B-A672-34853D8CDD97Q40180430-051C5116-4EFD-4F7B-AEDB-DCE9B08FEB2B
P2860
Development and clinical significance of a diagnostic assay based on the polymerase chain reaction for detection of human cytomegalovirus DNA in blood samples from immunocompromised patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 1992
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development and clinical signi ...... om immunocompromised patients.
@en
Development and clinical signi ...... om immunocompromised patients.
@nl
type
label
Development and clinical signi ...... om immunocompromised patients.
@en
Development and clinical signi ...... om immunocompromised patients.
@nl
prefLabel
Development and clinical signi ...... om immunocompromised patients.
@en
Development and clinical signi ...... om immunocompromised patients.
@nl
P2093
P2860
P1476
Development and clinical signi ...... om immunocompromised patients.
@en
P2093
Milanesi G
Percivalle E
Revello MG
Zavattoni M
P2860
P304
P407
P577
1992-02-01T00:00:00Z